Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
SD Biosensor G6PD Analyzer
+ Pointe Scientific Test Kit
+ HemoCue System
Anemia+9
+ Anemia, Hemolytic
+ Anemia, Hemolytic, Congenital
Diagnostic Study
Summary
Study start date: May 13, 2019
Actual date on which the first participant was enrolled.This is a cross-sectional diagnostic accuracy study with up to 250 participants with a goal of obtaining 20 deficient and 20 intermediate samples. The clinic will recruit and consent study participants. Clinic staff will draw 3 whole blood samples and obtain finger stick capillary blood. G6PD activity is reported in terms of grams of hemoglobin (Hb), hence the hemoglobin concentration must be measured. Clinic staff will perform the investigational Standard Diagnostics (SD) Biosensor point-of-care (POC) test for glucose-6-phosphate dehydrogenase (G6PD) deficiency and a HemoCue® hemoglobin test on finger stick capillary blood and on the venous blood samples. Another venous blood sample will be sent to a clinical laboratory improvement amendments (CLIA)-certified laboratory for reference testing by the gold standard assays: * G6PD measurement by spectrophotometry using the Pointe Scientific G6PD reference assay * hemoglobin measurement by a hematology analyzer Individuals identified as G6PD deficient with the reference test will be notified of their results by the clinic and referred to their physician for follow-up.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.250 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: -Willingness to provide consent Exclusion Criteria: -Blood transfusion in the past 90 days by self-report
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Fred Hutchison Prevention Center
Seattle, United StatesOpen Fred Hutchison Prevention Center in Google Maps